Skip to main content
. 2021 Apr 16;6(16):10921–10935. doi: 10.1021/acsomega.1c00681

Figure 2.

Figure 2

Ligand-based pharmacophore model (PH9) for CCR5 inhibitors: (A) three-dimensional (3D) spatial arrangement and distance constraints between the chemical features of the pharmacophore model represented by blue (cationic center, Cat), orange (aromatic center, Aro), and green (hydrophobic, Hyd) spheres. (B) Overlay of the crystal coordinates of MVC on the pharmacophore model (PH9).